Case commentary · Independent analysis · 2026-11-10

Truinject Corp. v. Galderma S.A. (Federal Circuit 2026): A Case Commentary on Damages, Causation and Preserving a Commercial Claim

Educational purposes only, not legal advice. Independent commentary by a non-attorney; not filed with any court. Read the court’s original opinion for the authoritative text.

Case: Truinject Corp. v. Galderma S.A., No. 2025-1268, slip op. (Fed. Cir. Oct. 1, 2026) (nonprecedential)

damagescausationtrade secretsexclusive negotiation agreementforfeitureFederal Circuit

Background

Thomas Guerriero’s commentary begins with a hard business lesson: a failed commercial relationship can produce a compelling story of lost opportunity without producing a legally sustainable claim for damages. The decision is expressly nonprecedential.

Truinject was developing Kate, a dermal-injection training system pairing a lifelike mannequin head with a syringe that tracks needle depth, angle and position. It signed a Confidential Disclosure Agreement with Galderma on 23 October 2014 and an Exclusive Negotiation Agreement on 5 November 2014, which barred other partnerships for 90 days; Galderma paid $75,000. To comply, Truinject cancelled a 7 November meeting with Allergan, whose representative later testified his objective had been to offer a $100 million upfront payment — though formal due diligence had not occurred. Talks with Galderma ended in January 2015.

Holding

The Federal Circuit affirmed judgment for Galderma. Truinject had forfeited its basis for challenging dismissal of the tortious-interference claim, and its attack on the no-damages ruling did not establish a basis for relief. Because Truinject sought no relief on appeal besides damages, the contract and trade-secret claims failed with that theory.

Reasoning

The problem was chronology and causation. The alleged disclosures began on 15 December 2014, after the November cancellation, so those later breaches could not have caused it — a conclusion Truinject did not challenge on appeal.

On appeal Truinject proposed using the Allergan opportunity as a benchmark of Kate’s market value. The court did not decide whether that theory was sound; it held it had not been adequately presented below. In the opinion’s words, a few passing lines buried in the opposition to summary judgment is not enough.

Practical takeaways (general observations, not advice)

Distinguish an opportunity from a concluded deal. Keep a dated chronology. Connect any valuation to a causal account. Make competing damages explanations explicit for counsel. Do not treat an appeal as a second chance to present the case.

Source

More from Thomas Guerriero

See all research and commentary at Research, and the main hub at ThomasGuerriero.com. Also: ThomasAGuerrieroPhD.com · ThomasAGuerriero.com.

For educational purposes only; not legal advice. This page summarises independent commentary on a public court opinion and links to the original.

Pursue greatness

Don't get left behind. Chase greatness.

If you want help growing your business, team, or just want to pursue greatness yourself, book a free 15 minute call at the link below.

cal.com/thomas-guerriero-gvx0zs/15min